Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman RS, Zeevi E, Munster M, Blat R, Tempel Brami C, Cahal S, Itzhaki A, Giladi M, Kirson ED, Weinberg U, Kinzel A, Palti Y. Voloshin T, et al. Among authors: tempel brami c. Cancer Immunol Immunother. 2020 Jul;69(7):1191-1204. doi: 10.1007/s00262-020-02534-7. Epub 2020 Mar 6. Cancer Immunol Immunother. 2020. PMID: 32144446 Free PMC article.
Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
Mumblat H, Martinez-Conde A, Braten O, Munster M, Dor-On E, Schneiderman RS, Porat Y, Voloshin T, Davidi S, Blatt R, Shteingauz A, Tempel-Brami C, Zeevi E, Lajterer C, Shmueli Y, Danilov S, Haber A, Giladi M, Weinberg U, Kinzel A, Palti Y. Mumblat H, et al. Among authors: tempel brami c. Lung Cancer. 2021 Oct;160:99-110. doi: 10.1016/j.lungcan.2021.08.011. Epub 2021 Aug 27. Lung Cancer. 2021. PMID: 34482104 Free article.
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo.
Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, Zeevi E, Frechtel-Gerzi R, Ene H, Dor-On E, Voloshin T, Tzchori I, Haber A, Giladi M, Kinzel A, Weinberg U, Palti Y. Davidi S, et al. Among authors: tempel brami c. Cancers (Basel). 2022 Jun 15;14(12):2959. doi: 10.3390/cancers14122959. Cancers (Basel). 2022. PMID: 35740624 Free PMC article.
Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood-Brain Barrier In Vitro and In Vivo.
Salvador E, Kessler AF, Domröse D, Hörmann J, Schaeffer C, Giniunaite A, Burek M, Tempel-Brami C, Voloshin T, Volodin A, Zeidan A, Giladi M, Ernestus RI, Löhr M, Förster CY, Hagemann C. Salvador E, et al. Among authors: tempel brami c. Biomolecules. 2022 Sep 22;12(10):1348. doi: 10.3390/biom12101348. Biomolecules. 2022. PMID: 36291557 Free PMC article.
Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model.
Barsheshet Y, Voloshin T, Brant B, Cohen G, Koren L, Blatt R, Cahal S, Haj Khalil T, Zemer Tov E, Paz R, Klein-Goldberg A, Tempel-Brami C, Jacobovitch S, Volodin A, Kan T, Koltun B, David C, Haber A, Giladi M, Weinberg U, Palti Y. Barsheshet Y, et al. Among authors: tempel brami c. Int J Mol Sci. 2022 Nov 15;23(22):14073. doi: 10.3390/ijms232214073. Int J Mol Sci. 2022. PMID: 36430552 Free PMC article.
Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959.
Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, Zeevi E, Frechtel-Gerzi R, Ene H, Dor-On E, Voloshin T, Tzchori I, Haber A, Giladi M, Kinzel A, Weinberg U, Palti Y. Davidi S, et al. Among authors: tempel brami c. Cancers (Basel). 2023 Feb 13;15(4):1182. doi: 10.3390/cancers15041182. Cancers (Basel). 2023. PMID: 36831698 Free PMC article.
MRI findings after hyperbaric oxygen-induced seizures.
Domachevsky L, Pick CG, Peled N, Gomori JM, Abramovich A, Tempel-Brami C. Domachevsky L, et al. Among authors: tempel brami c. Epilepsy Res. 2013 Jul;105(1-2):62-8. doi: 10.1016/j.eplepsyres.2013.01.008. Epub 2013 Jan 26. Epilepsy Res. 2013. PMID: 23357721
A mouse model of blast-induced mild traumatic brain injury.
Rubovitch V, Ten-Bosch M, Zohar O, Harrison CR, Tempel-Brami C, Stein E, Hoffer BJ, Balaban CD, Schreiber S, Chiu WT, Pick CG. Rubovitch V, et al. Among authors: tempel brami c. Exp Neurol. 2011 Dec;232(2):280-9. doi: 10.1016/j.expneurol.2011.09.018. Epub 2011 Sep 17. Exp Neurol. 2011. PMID: 21946269 Free PMC article.
Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse model.
Lifshitz V, Weiss R, Benromano T, Kfir E, Blumenfeld-Katzir T, Tempel-Brami C, Assaf Y, Xia W, Wyss-Coray T, Weiner HL, Frenkel D. Lifshitz V, et al. Among authors: tempel brami c. Neurobiol Aging. 2012 Feb;33(2):432.e1-432.e13. doi: 10.1016/j.neurobiolaging.2011.01.006. Epub 2011 Mar 2. Neurobiol Aging. 2012. PMID: 21371785 Free PMC article.
16 results